GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Therapeutic Solutions International Inc (OTCPK:TSOI) » Definitions » Pretax Margin %

Therapeutic Solutions International (Therapeutic Solutions International) Pretax Margin % : -1,995.83% (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Therapeutic Solutions International Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Therapeutic Solutions International's Pre-Tax Income for the three months ended in Dec. 2023 was $-0.48 Mil. Therapeutic Solutions International's Revenue for the three months ended in Dec. 2023 was $0.02 Mil. Therefore, Therapeutic Solutions International's pretax margin for the quarter that ended in Dec. 2023 was -1,995.83%.

The historical rank and industry rank for Therapeutic Solutions International's Pretax Margin % or its related term are showing as below:

TSOI' s Pretax Margin % Range Over the Past 10 Years
Min: -62233.33   Med: -6285.19   Max: -1872.46
Current: -2244.44


TSOI's Pretax Margin % is ranked worse than
81.42% of 1028 companies
in the Biotechnology industry
Industry Median: -155.98 vs TSOI: -2244.44

Therapeutic Solutions International Pretax Margin % Historical Data

The historical data trend for Therapeutic Solutions International's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Therapeutic Solutions International Pretax Margin % Chart

Therapeutic Solutions International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6,285.19 -3,492.06 -2,028.08 -1,872.46 -2,244.44

Therapeutic Solutions International Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12,655.56 -2,513.04 -2,161.54 -2,319.23 -1,995.83

Competitive Comparison of Therapeutic Solutions International's Pretax Margin %

For the Biotechnology subindustry, Therapeutic Solutions International's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Therapeutic Solutions International's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Therapeutic Solutions International's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Therapeutic Solutions International's Pretax Margin % falls into.



Therapeutic Solutions International Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Therapeutic Solutions International's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-2.222/0.099
=-2,244.44 %

Therapeutic Solutions International's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-0.479/0.024
=-1,995.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Therapeutic Solutions International  (OTCPK:TSOI) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Therapeutic Solutions International Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Therapeutic Solutions International's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Therapeutic Solutions International (Therapeutic Solutions International) Business Description

Traded in Other Exchanges
N/A
Address
701 Wild Rose Lane, Elk City, ID, USA, 83525
Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for the development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).
Executives
Thomas Ichim director 211 E. OSBORN RD, PHOENIX AZ 85012
Gerry B Berg officer: CFO 1658 AVENIDA LA POSTA, ENCINITAS CA 92024
Timothy G Dixon director, officer: Chairman, President, CEO 4093 OCEANSIDE BLVD., SUITE B, OCEANSIDE CA 92056
Barry Glassman officer: VP, Training & Education 2051 ELBOW LANE, ALLENTOWN PA 18103
James P Boyd director, 10 percent owner PO BOX 2145, RANCHO SANTA FE CA 92067

Therapeutic Solutions International (Therapeutic Solutions International) Headlines

From GuruFocus